Phase II, Single Arm Trial of Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-Risk Patients With Metastatic Renal Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2016
At a glance
- Drugs Gemcitabine (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- 02 Apr 2015 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov.
- 29 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as per ClinicalTrials.gov record.
- 29 Jan 2014 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.